Trial Profile
A Retrospective study of Ga-68 DOTATATE scan for the diagnosis and management of Neuroendocrine tumours
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Jun 2018
Price :
$35
*
At a glance
- Drugs Gallium 68-DOTATATE (Primary)
- Indications Neuroendocrine tumours
- Focus Diagnostic use
- 13 Jun 2018 New trial record
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology